CARDURA XL (doxazosin mesylate)
Cardura XL treats the signs and symptoms associated with benign prostatic hyperplasia (BPH). It helps patients who experience urinary difficulties such as frequency, nocturia, weak stream, and incomplete emptying. This medication is specifically used for prostate-related symptoms and is not used to manage hypertension.
How CARDURA XL Works
This medication works by selectively blocking alpha 1 adrenergic receptors, which are found in high density within the prostate and bladder neck. By inhibiting these receptors, the drug reduces smooth muscle tone and decreases urethral resistance. This action helps improve urine flow and relieves the symptoms caused by the dynamic component of the condition.
Details
- Status
- Prescription
- First Approved
- 2005-02-22
- Routes
- ORAL
- Dosage Forms
- TABLET, EXTENDED RELEASE
CARDURA XL Approval History
What CARDURA XL Treats
1 indicationsCARDURA XL is approved for 1 conditions since its original approval in 2005. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Benign Prostatic Hyperplasia
CARDURA XL Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CARDURA XL
3 of 12FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CARDURA XL FDA Label Details
Indications & Usage
FDA Label (PDF)CARDURA XL is indicated for the treatment of Benign Prostatic Hyperplasia.
Track CARDURA XL with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.